论文部分内容阅读
40例PCOS患者分为肥胖组和非肥胖组,检测Met治疗前后患者的血脂谱、胰岛素抵抗指数(HOMA-IR)、C反应蛋白(CRP)及白介素2(IL-2)的变化。结果:肥胖组的血脂谱和HOMA-IR高于非肥胖组,两组的CRP及IL-2差异没有统计学意义。经过16周Met治疗后,两组的血脂谱、HOMA-IR、CRP及IL-2明显下降。结论:Met可以改善PCOS的患者的IR及炎症。
Forty patients with PCOS were divided into obese group and non-obese group. The serum lipid profile, insulin resistance index (HOMA-IR), C-reactive protein (CRP) and interleukin 2 (IL-2) levels were measured before and after Met treatment. Results: The lipid profile and HOMA-IR of obese group were higher than those of non-obese group, and the differences of CRP and IL-2 between two groups were not statistically significant. After 16 weeks of Met treatment, the serum lipid profiles, HOMA-IR, CRP and IL-2 decreased significantly in both groups. Conclusion: Met can improve IR and inflammation in patients with PCOS.